missing translation for 'onlineSavingsMsg'
Learn More
Please login to your online account to display your discounted pricing

DLL4 Recombinant Human Protein, hIgG1-Fc Tag, Invitrogen™ Sino Biological™ DFS Item

This recombinant human protein is expressed from a DNA sequence encoding the extracellular domain (Met 1-Pro 524) of human DLL4 preprotein (NP_061947.1) fused to the Fc region of human IgG1 at the C-terminus

$102.00 - $1,346.00


Purity ≥90% by SDS-PAGE
Endotoxin Concentration <1 EU/μg
Format Lyophilized
Gene Alias DLL4, mgC126344, hdelta2
View More Specs

Products 4
Catalog Number Mfr. No. Quantity Price Quantity  
Catalog Number Mfr. No. Quantity Price Quantity  
10171H02H5 View Documents Life Technologies
5μg Each for $102.00
10171H02H25 View Documents Life Technologies
5 x 5μg Each for $222.00
10171H02H50 View Documents Life Technologies
50μg Each for $398.00
10171H02HL View Documents Life Technologies
5 x 50μg Each for $1,346.00


Delta-like 4 (Drosophila) (DLL4) recombinant human protein is supplied as a lyophilized powder. This protein is suitable for use in protein studies such as protein structure analysis and protein-protein interactions. In general, recombinant proteins can also be used as an immunogen, as a protein standard, or in cell biology research applications.
Background: Delta-like protein 4 (DLL4) is a type I membrane-bound Notch ligand characterized by an extracellular region containing several EGF-like domains and a DSL domain required for receptor binding, and is suggested to play a key role in vascular development and tumorangiogenesis. The Notch pathway is an evolutionary conserved intercellular signaling pathway involved in numerous biological processes including cell fate determination, cellular differentiation, proliferation, survival, and apoptosis. In mammalian cells, five Notch ligands (Jagged1, 2, DLL1, 3, 4) and four Notch receptors (Notch1-4) have been identified, and ligand-receptor interactions results in proteolysis and translocation of the Notch intracellular domain. As a ligand for Notch1 and Notch 4, DLL4 is selectively expressed in the developing endothelium and in some tumor endothelium, and is induced by vascular endothelial growth factor (VEGF)-A and hypoxia. In recent studies, it has been revealed that this DLL4 inhibition may paradoxically lead to increased angiogenesis but poor tumor growth because of the nonfunctional neovascularization, and constitutive expression of DLL4 may lead to a lethal lymphoproliferative disease. Accordingly, this may provide a new therapeutic approach for certain carcinomas.
  • N-terminal Sequence Analysis: Ser 27
  • Activity: measured by its binding ability in a functional ELISA; immobilized human DLL4 at 10μg/mL (100μL/well) has been shown to bind biotinylated mouse NOTCH1-His, the EC50 of biotinylated mouse NOTCH1-His is 40ng/mL
  • Formulation: lyophilized in 140mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 1.8mM KH2PO4, pH 7.4, 5% mannitol, 5% trehalose, 0.02% Tween™-80
  • Reconstitution: Dissolve the protein in sterile double-distilled water to a concentration of 0.2mg/mL or lower; aliquot and use as soon as possible

Manufactured by Sino Biological (China).



≥90% by SDS-PAGE
<1 EU/μg
DLL4, mgC126344, hdelta2

For Research Use Only. Not for use in diagnostic procedures.